These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35101227)

  • 1. A brief history of RAS and the RAS Initiative.
    McCormick F
    Adv Cancer Res; 2022; 153():1-27. PubMed ID: 35101227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging strategies to target RAS signaling in human cancer therapy.
    Chen K; Zhang Y; Qian L; Wang P
    J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras and exosome signaling.
    Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
    Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.
    Shetu SA; Bandyopadhyay D
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
    Roskoski R
    Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RAS-Effector Interaction as a Drug Target.
    Keeton AB; Salter EA; Piazza GA
    Cancer Res; 2017 Jan; 77(2):221-226. PubMed ID: 28062402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.
    Stalnecker CA; Der CJ
    Sci Signal; 2020 Mar; 13(624):. PubMed ID: 32209699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS-targeted therapies: is the undruggable drugged?
    Moore AR; Rosenberg SC; McCormick F; Malek S
    Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology, pathology, and therapeutic targeting of RAS.
    Rhett JM; Khan I; O'Bryan JP
    Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in cancer drug discovery targeting RAS.
    Wilson CY; Tolias P
    Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting oncogenic Ras signaling in hematologic malignancies.
    Ward AF; Braun BS; Shannon KM
    Blood; 2012 Oct; 120(17):3397-406. PubMed ID: 22898602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
    Chuang HC; Huang PH; Kulp SK; Chen CS
    Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras proteins as therapeutic targets.
    Chakraborty A; Linnane E; Ross S
    Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the Small GTPase Ras and Its Relevance to Human Disease.
    Kulhanek KR; Roose JP; Rubio I
    Methods Mol Biol; 2021; 2262():19-43. PubMed ID: 33977469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ; Zhou H; Lu Q
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding and drugging RAS: 40 years to break the tip of the iceberg.
    Brady DC; Hmeljak J; Dar AC
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35244677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.
    Vasan N; Boyer JL; Herbst RS
    Clin Cancer Res; 2014 Aug; 20(15):3921-30. PubMed ID: 24893629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS proto-oncogene in medullary thyroid carcinoma.
    Moura MM; Cavaco BM; Leite V
    Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.